Clinical Trial Update: Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating pembrolizumab with gemcitabine and concurrent hypofractionated radiation therapy for muscle-invasive bladder cancer; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Gemzar (gemcitabine)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: NYU Langone Health | Conditions: Muscle-invasive Urothelial Cancer of the Bladder | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-07